JPRN-UMIN000019519已完成未知
A pooled data analysis of four randomized phase III trials (SPIRITS, GC0301/TOP-002, START, G-SOX) using individual patient data in advanced gastric cancer. - A pooled data analysis of advanced gastric cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 1,700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Others,meta-analysis etc
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Any cases who registered other randomized studies or phase I or II studies.
研究者
相似试验
已完成
不适用
An ancillary study of "a randomized phase 2 study of TS-1 versus CDDP+VNR for adjuvant therapy in patients with non-small cell lung cancer(UMIN000027435)" - investigation of effect prediction bio-marker for adjuvant therapy.on-small-cell lung cancerJPRN-UMIN000027436Clinical Research Support Center Kyushu190
进行中（未招募）
1 期
A clinical study evaluating nivolumab-containing treatments in patients with advanced non-small cell lung cancer after failing previous PD-[L]1 therapy and chemotherapyStage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum- Based Chemotherapy and Anti-PD-1 (L1) ImmunotherapyMedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004283-65-NOBristol-Myers Squibb International Corporation550
进行中（未招募）
1 期
A clinical study evaluating nivolumab-containing treatments in patients with advanced non-small cell lung cancer after failing previous PD-[L]1 therapy and chemotherapyStage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum- Based Chemotherapy and Anti-PD-1 (L1) ImmunotherapyMedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004283-65-FRBristol-Myers Squibb International Corporation550
进行中（未招募）
1 期
A clinical study evaluating nivolumab-containing treatments in patients with advanced non-small cell lung cancer after failing previous PD-[L]1 therapy and chemotherapyStage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum- Based Chemotherapy and Anti-PD-1 (L1) ImmunotherapyMedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004283-65-DKBristol-Myers Squibb International Corporation550
进行中（未招募）
1 期
A clinical study evaluating nivolumab-containing treatments in patients with advanced non-small cell lung cancer after failing previous PD-[L]1 therapy and chemotherapyStage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum- Based Chemotherapy and Anti-PD-1 (L1) ImmunotherapyMedDRA version: 21.1Level: PTClassification code 10029515Term: Non-small cell lung cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004283-65-PLBristol-Myers Squibb International Corporation550